Aditum Bio

Aditum Bio is a biotech venture capital firm dedicated to translating scientific discoveries into innovative medicines. Founded in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research, Dr. Mark Fishman, the firm operates with a mission to provide patients access to medicines that might not otherwise be developed. Aditum Bio's unique model combines scientific expertise with operational capabilities to accelerate drug development, enabling rapid company formation and execution to bring therapies to patients faster.

The firm's investment strategy focuses on in-licensing promising drug candidates targeting fundamental disease mechanisms and spinning out individual companies to advance these candidates through Phase II clinical trials. Aditum Bio's portfolio includes companies like Versanis Bio, formed in 2021 to develop bimagrumab for metabolic diseases and obesity, and Vitalli Bio, established in 2023 to develop therapies for immunological disorders. The firm emphasizes a patient-centric, collaborative, curious, and courageous approach to addressing significant unmet medical needs.

Aditum Bio's track record demonstrates its commitment to improving public health by accelerating R&D in disease areas with large and targeted patient populations. By leveraging data, software, and technology, the firm aims to bring innovative medicines through the clinical trial phase more quickly and cost-effectively than traditional pharmaceutical companies. This approach has led to the formation of multiple portfolio companies, each dedicated to advancing specific therapeutic areas, thereby contributing to the broader goal of enhancing health outcomes across diverse medical fields.